Revumenib 160mg Tablet – Imported | Lucius Pharmaceuticals

Product Overview

Revumenib 160mg Tablet – Imported is a specialized prescription anticancer medicine containing revumenib, a targeted menin inhibitor. Revumenib is used to treat certain patients with acute leukemia associated with specific genetic changes, particularly susceptible nucleophosmin 1 (NPM1) mutations or KMT2A rearrangements, depending on the approved indication and applicable prescribing information.

Revumenib works by disrupting the interaction between menin and the KMT2A protein, which can contribute to abnormal gene expression and the development of leukemia cells. By targeting this pathway, the medicine can help restore normal cellular differentiation and interfere with leukemia-cell growth.

The product details provided for this listing identify Lucius Pharmaceuticals as the manufacturer, with a pack size of 30 tablets. Because revumenib is a specialized oncology medicine, its use requires an experienced hematologist or oncologist, appropriate diagnostic testing, and close monitoring.

If you are looking for Revumenib 160mg Tablets in Pakistan, contact MedicineWalyDost.com to confirm product availability, current pricing, manufacturer details, prescription requirements, and delivery arrangements.

Key Product Information

• Product Name: Revumenib 160mg Tablet
• Generic Name: Revumenib
• Strength: 160mg
• Dosage Form: Tablet
• Product Type: Imported medicine
• Manufacturer: Lucius Pharmaceuticals
• Pack Size: 30 Tablets
• Therapeutic Category: Targeted anticancer therapy; menin inhibitor
• Main Treatment Area: Certain genetically defined acute leukemias
• Prescription Requirement: Specialist-prescribed medicine

The manufacturer, dosage form, product registration, and packaging should be verified against the actual imported product and its official prescribing information before use.

What Is Revumenib 160mg Used For?

Revumenib is a targeted treatment for specific forms of acute leukemia in patients whose disease has relevant genetic characteristics. The precise approved indication depends on the patient’s diagnosis, previous treatments, and the applicable regulatory label.

An oncology specialist may consider revumenib for eligible patients with:

• KMT2A-rearranged acute leukemia: A genetically defined leukemia associated with rearrangements involving the KMT2A gene.
• NPM1-mutated acute myeloid leukemia (AML): Certain cases of AML associated with mutations in the NPM1 gene, where the relevant approved indication applies.
• Relapsed or refractory disease: Specific leukemia settings in which the disease has returned or has not responded adequately to previous treatment, according to the applicable label.

Revumenib is not a general treatment for all leukemias. Genetic testing is essential to establish whether a patient’s disease matches the relevant treatment indication.

How Does Revumenib Work?

Revumenib inhibits the interaction between menin and the KMT2A protein. This interaction can contribute to the abnormal gene-expression patterns that maintain leukemia cells in an immature state.

By blocking this interaction, revumenib can help alter leukemia-related gene expression and promote differentiation of susceptible leukemia cells. This targeted mechanism differs from conventional chemotherapy, although revumenib can still cause serious adverse effects and requires careful monitoring.

Treatment response varies between patients. The treating specialist assesses the disease characteristics, blood counts, treatment response, and safety findings throughout therapy.

Potential Benefits of Revumenib 160mg Tablets

When prescribed for an appropriate, genetically defined leukemia, revumenib may offer the following potential benefits:

• Targets a specific molecular pathway involved in certain leukemias.
• Provides a targeted treatment option for eligible patients.
• May be considered in particular relapsed or refractory disease settings.
• Offers an oral treatment formulation where the specific product is appropriately authorized.
• Can form part of a specialist-directed treatment strategy based on genetic and clinical findings.

Individual outcomes vary, and treatment effectiveness cannot be guaranteed. Revumenib is not suitable for every patient with acute leukemia.

How to Take Revumenib 160mg Tablets

Revumenib must be taken exactly as prescribed by the treating hematologist or oncologist.

The appropriate dose and schedule depend on the patient’s treatment plan, body size where relevant, interacting medicines, laboratory results, and the specific approved product information.

Important administration precautions include:

• Follow the exact dosing schedule provided by the oncology team.
• Take the medicine according to the instructions supplied with the specific product.
• Do not change the dose, take extra tablets, or discontinue treatment without specialist advice.
• Ask the oncology team what to do if a dose is missed or vomiting occurs after a dose.
• Attend all scheduled blood tests, electrocardiograms (ECGs), and follow-up appointments.

Important: A 160mg tablet strength does not establish the correct total dose or number of tablets for an individual patient. Do not calculate or adjust a regimen based solely on the strength printed on the package.

Possible Side Effects of Revumenib

Revumenib can cause adverse effects that require medical monitoring. Potential side effects may include:

• Nausea and vomiting
• Diarrhea
• Fatigue
• Fever
• Changes in blood-cell counts
• Reduced appetite
• Electrolyte abnormalities
• Liver enzyme abnormalities

The side-effect profile can vary depending on the patient’s condition and any other medicines used alongside treatment.

Serious Side Effects and Warnings

Differentiation syndrome: Revumenib may cause differentiation syndrome, a potentially life-threatening complication associated with the rapid maturation of leukemia cells. Symptoms can include fever, difficulty breathing, swelling, rapid weight gain, low blood pressure, or kidney problems. Seek urgent medical assessment if these symptoms occur.

QT interval prolongation: Revumenib may affect the heart’s electrical activity and prolong the QT interval, potentially causing dangerous heart-rhythm abnormalities. ECG and electrolyte monitoring may be required.

Low blood counts and infection: Patients with leukemia may already have reduced blood-cell counts, and treatment can contribute to additional complications. Report fever, unusual bleeding, or signs of infection promptly.

Liver abnormalities: Liver function may require monitoring during treatment.

This list is not exhaustive. Read the official product information and discuss all potential risks with the treating specialist.

Precautions and Warnings

Before starting Revumenib 160mg Tablets, tell your healthcare team about all medical conditions and medicines you use.

• Heart rhythm problems: Inform your doctor about any history of arrhythmia, prolonged QT interval, fainting, or significant heart disease.
• Electrolyte levels: Low potassium or magnesium can increase heart-rhythm risks and may need correction.
• Drug interactions: Some medicines can increase revumenib exposure or further prolong the QT interval.
• Blood counts: Regular laboratory monitoring is necessary during treatment.
• Infection risk: Report fever or other possible signs of infection promptly.
• Pregnancy: Discuss potential fetal risks and appropriate contraception with your oncology team before treatment.
• Breastfeeding: Ask your specialist whether breastfeeding must be avoided during treatment and for the period specified by the official product information.
• Other medical conditions: Report liver problems and any other significant health concerns before treatment begins.

Do not start revumenib without specialist supervision.

Drug Interactions

Revumenib can interact with medicines that affect drug metabolism or cardiac electrical activity.

Tell your oncologist and pharmacist about all prescription medicines, over-the-counter products, vitamins, and herbal supplements you use.

Particular attention may be required for:

• Strong or moderate CYP3A inhibitors: These can increase revumenib exposure and may require specialist-directed dose adjustments.
• CYP3A inducers: These can change medicine exposure and potentially affect treatment effectiveness.
• QT-prolonging medicines: Certain antibiotics, antifungals, antiarrhythmics, and other medicines may increase the risk of heart-rhythm complications.
• Medicines affecting electrolytes: Some treatments can lower potassium or magnesium and increase cardiac risks.
• Herbal supplements: Some products can affect drug metabolism and should not be used without professional advice.

Never start, stop, or change another medicine without consulting the oncology team.

Who Should Use Revumenib 160mg Tablets?

Revumenib may be appropriate for patients with specific genetically defined forms of acute leukemia when the treatment meets the applicable approved indication.

Before prescribing, the specialist considers:

• The confirmed leukemia diagnosis.
• Results of relevant genetic or molecular testing.
• Previous treatment and disease response.
• Heart rhythm and ECG findings.
• Blood counts, electrolyte levels, and liver function.
• Other medicines and potential drug interactions.

Revumenib is not intended for self-treatment or for use without appropriate diagnostic testing and specialist oversight.

Storage Instructions

• Follow the storage instructions on the manufacturer’s label and official product leaflet.
• Keep the medicine in its original packaging when appropriate.
• Protect it from unsuitable temperature and moisture conditions.
• Keep it out of reach of children.
• Check the expiry date and packaging integrity before use.

Storage requirements should be confirmed for the specific imported product supplied.

Why Choose MedicineWalyDost.com?

MedicineWalyDost.com provides a platform for enquiries about imported medicines and specialty healthcare products.

For Revumenib 160mg Tablets, customers can enquire about:

• Current product availability.
• Latest price in Pakistan.
• Manufacturer and packaging details.
• Prescription and documentation requirements.
• Available delivery arrangements.

Product authenticity, regulatory authorization, and the suitability of the medicine should be verified before purchase. Specialized anticancer medicines should be obtained through appropriate, authorized supply channels.

Frequently Asked Questions (FAQs)

1. What is Revumenib 160mg Tablet used for?

Revumenib is a targeted menin inhibitor used for certain genetically defined acute leukemias, depending on the approved indication and the patient’s clinical circumstances.

2. Who is the manufacturer of Revumenib 160mg Tablets?

The manufacturer provided for this listing is Lucius Pharmaceuticals. Confirm the manufacturer and product details against the actual packaging before purchase.

3. What is the pack size of Revumenib 160mg Tablets?

The specified pack size is 30 tablets.

4. How does revumenib work?

Revumenib blocks the menin-KMT2A interaction, targeting a molecular pathway involved in the development and maintenance of certain leukemia cells.

5. Is Revumenib suitable for every type of leukemia?

No. Its use depends on the specific leukemia diagnosis, relevant genetic findings, previous treatment, and applicable prescribing information.

6. What are the serious risks of revumenib?

Important risks include differentiation syndrome and QT interval prolongation, as well as possible blood-count, electrolyte, and liver abnormalities. Specialist monitoring is essential.

7. Can Revumenib 160mg Tablets be taken without a prescription?

No. Revumenib requires a specialist prescription, appropriate diagnostic confirmation, and regular medical monitoring.

8. What is the price of Revumenib 160mg Tablets in Pakistan?

The current price has not been verified here. Contact MedicineWalyDost.com to enquire about the latest price and availability.

9. Where can I enquire about Revumenib 160mg Tablets?

Visit MedicineWalyDost.com to enquire about product availability, current pricing, packaging details, prescription requirements, and delivery arrangements.

Conclusion

Revumenib 160mg Tablet is a targeted prescription anticancer medicine that inhibits the menin pathway and may be used for certain genetically defined acute leukemias. Its use requires specialist assessment, diagnostic confirmation, and careful monitoring for serious adverse effects.

The supplied product listing details are Revumenib 160mg Tablet – Imported, Lucius Pharmaceuticals, pack of 30 tablets. Confirm the product’s authenticity, regulatory status, formulation, and prescribing information before use.

Contact MedicineWalyDost.com to confirm availability, current price in Pakistan, prescription requirements, and delivery details.